Cargando…
Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
Obstructive sleep apnea (OSA) is a severe sleep disorder associated with intermittent hypoxia and sleep fragmentation. Cognitive impairment is a signifi- cant and common OSA complication often described in such patients. The most commonly utilized methods in clinical OSA treatment are oral appliance...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507626/ https://www.ncbi.nlm.nih.gov/pubmed/37731463 http://dx.doi.org/10.3389/fncel.2023.1222626 |
_version_ | 1785107355187281920 |
---|---|
author | He, Daqiang Chen, Jian Du, Xiaoxue Xu, Linhao |
author_facet | He, Daqiang Chen, Jian Du, Xiaoxue Xu, Linhao |
author_sort | He, Daqiang |
collection | PubMed |
description | Obstructive sleep apnea (OSA) is a severe sleep disorder associated with intermittent hypoxia and sleep fragmentation. Cognitive impairment is a signifi- cant and common OSA complication often described in such patients. The most commonly utilized methods in clinical OSA treatment are oral appliances and continuous positive airway pressure (CPAP). However, the current therapeutic methods for improving cognitive function could not achieve the expected efficacy in same patients. Therefore, further understanding the molecular mechanism behind cognitive dysfunction in OSA disease will provide new treatment methods and targets. This review briefly summarized the clinical manifestations of cognitive impairment in OSA disease. Moreover, the pathophysiological molecular mechanism of OSA was outlined. Our study concluded that both SF and IH could induce cognitive impairment by multiple signaling pathways, such as oxidative stress activation, inflammation, and apoptosis. However, there is a lack of effective drug therapy for cognitive impairment in OSA. Finally, the therapeutic potential of some novel compounds and herbal medicine was evaluated on attenuating cognitive impairment based on certain preclinical studies. |
format | Online Article Text |
id | pubmed-10507626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105076262023-09-20 Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea He, Daqiang Chen, Jian Du, Xiaoxue Xu, Linhao Front Cell Neurosci Neuroscience Obstructive sleep apnea (OSA) is a severe sleep disorder associated with intermittent hypoxia and sleep fragmentation. Cognitive impairment is a signifi- cant and common OSA complication often described in such patients. The most commonly utilized methods in clinical OSA treatment are oral appliances and continuous positive airway pressure (CPAP). However, the current therapeutic methods for improving cognitive function could not achieve the expected efficacy in same patients. Therefore, further understanding the molecular mechanism behind cognitive dysfunction in OSA disease will provide new treatment methods and targets. This review briefly summarized the clinical manifestations of cognitive impairment in OSA disease. Moreover, the pathophysiological molecular mechanism of OSA was outlined. Our study concluded that both SF and IH could induce cognitive impairment by multiple signaling pathways, such as oxidative stress activation, inflammation, and apoptosis. However, there is a lack of effective drug therapy for cognitive impairment in OSA. Finally, the therapeutic potential of some novel compounds and herbal medicine was evaluated on attenuating cognitive impairment based on certain preclinical studies. Frontiers Media S.A. 2023-09-04 /pmc/articles/PMC10507626/ /pubmed/37731463 http://dx.doi.org/10.3389/fncel.2023.1222626 Text en Copyright © 2023 He, Chen, Du and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience He, Daqiang Chen, Jian Du, Xiaoxue Xu, Linhao Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
title | Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
title_full | Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
title_fullStr | Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
title_full_unstemmed | Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
title_short | Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
title_sort | summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507626/ https://www.ncbi.nlm.nih.gov/pubmed/37731463 http://dx.doi.org/10.3389/fncel.2023.1222626 |
work_keys_str_mv | AT hedaqiang summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea AT chenjian summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea AT duxiaoxue summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea AT xulinhao summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea |